| 30.39 0.87 (2.95%) | 08-21 12:36 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 36.53 | 1-year : | 42.67 |
| Resists | First : | 31.28 | Second : | 36.53 |
| Pivot price | 29 |
|||
| Supports | First : | 28.13 |
Second : | 26.19 |
| MAs | MA(5) : | 29.85 |
MA(20) : | 28.64 |
| MA(100) : | 26.19 |
MA(250) : | 22.1 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 71.6  |
D(3) : | 76.7 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 31.73 | Low : | 10.06 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RCUS ] has closed below upper band by 7.7%. Bollinger Bands are 31.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 30.44 - 30.6 | 30.6 - 30.72 |
| Low: | 28.6 - 28.75 | 28.75 - 28.88 |
| Close: | 29.29 - 29.54 | 29.54 - 29.74 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Wed, 19 Aug 2026
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
Mon, 17 Aug 2026
Arcus Biosciences Inc (RCUS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Sat, 15 Aug 2026
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders - simplywall.st
Thu, 13 Aug 2026
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Tue, 11 Aug 2026
A New Arcus Employee Receives Options With a $28.72 Exercise Price - Stock Titan
Fri, 07 Aug 2026
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 126 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 28.7 (%) |
| Held by Institutions | 73.2 (%) |
| Shares Short | 12,560 (K) |
| Shares Short P.Month | 13,270 (K) |
| EPS | -3.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.03 |
| Profit Margin | 0 % |
| Operating Margin | -234.2 % |
| Return on Assets (ttm) | -30.4 % |
| Return on Equity (ttm) | -90.9 % |
| Qtrly Rev. Growth | -74.5 % |
| Gross Profit (p.s.) | -3.03 |
| Sales Per Share | 0.93 |
| EBITDA (p.s.) | -3.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -474 (M) |
| Levered Free Cash Flow | -271 (M) |
| PE Ratio | -7.7 |
| PEG Ratio | 0 |
| Price to Book value | 6.01 |
| Price to Sales | 32.59 |
| Price to Cash Flow | -8.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|